Senores Pharmaceuticals Limited

LISTED

Mainboard IPO · IPO Guide

📄 View RHP ✅ Check Allotment

Issue Price

₹372 – ₹391

Listed On

30 Dec 2024

Listing Price

₹600 (+53.45%)

Current Price LIVE

₹600 (+53.45%)

🧮

Lot Size Calculator

Application	Lots	Shares	Amount
Retail (Min)	1	38	₹14,858
Retail (Max)	13	494	₹1,93,154
S-HNI (Min)	14	532	₹2,08,012
S-HNI (Max)	67	2,546	₹9,95,486
B-HNI (Min)	68	2,584	₹10,10,344

Retail: ≤ ₹2L • S-HNI: ₹2L–₹10L • B-HNI: > ₹10L Cap Price: ₹391/sh

As per financials, Senores Pharmaceuticals Limited has shown good growth, RoNW is 23.6% and P/E is 213.53, 55.05 and 37.6 respectively as per FY23, FY24 and annualised FY25 earnings. So issue looks fully priced when compared with peers, but sudden rise in net-profit raises doubts. Company is in pharma business for global markets through its global research and marketing skills, which is highly competitive business segment. So, we give SUBSCRIBE rating for this IPO. Readers must consult a qualified financial advisor prior to making any actual investment decisions.

As on Date	QIB	NII	RII	Employee	Total
Shares Offered / Reserved	45,93,216	23,19,879	15,46,586	75,000	85,34,681
Day 1 20-12-24	28,766 (0.01)	38,74,442 (1.67)	1,11,42,094 (7.2)	1,41,360 (1.88)	1,51,86,662 (1.78)
Day 2 23-12-24	16,11,048 (0.35)	5,71,34,976 (24.63)	5,94,00,650 (38.41)	7,60,152 (10.14)	11,89,06,826 (13.93)
Day 3 24-12-24	43,47,78,102 (94.66)	22,29,63,100 (96.11)	13,79,92,554 (89.22)	14,94,122 (19.92)	79,72,27,878 (93.41)

Open Date	Dec 20, 2024
Close Date	Dec 24, 2024
Allotment Date	Dec 27, 2024
Listing Date	Dec 30, 2024
Face Value	₹ 10 Per Equity Share
Issue Price	₹ 372 to ₹ 391 Per Equity Share
Issue Size	Total Equity Shares of 1,48,87,723 with aggregating up to Rs 582.11/- Cr Fresh Issue of Up to 1,27,87,723 with aggregating up to Rs 500/- Cr Offer for sale Up to 21,00,000 with aggregating up to Rs 82.11/- Cr
Retail Min Lot	1 Lot (38 Shares - ₹ 14,858)
S-HNI Min Lot	14 Lots (532 Shares - ₹ 2,08,012)
Allocation	QIB: 75% \| NII: 15% \| RII: 10%
Promoter Shareholding	66.67% (Pre-Issue) 45.76% (Post-Issue)
Registrar	Link Intime India Private Limited
Lead Manager	Ambit Private Limited, Equirus Capital Private Limited, Nuvama Wealth Management Limited

Company	P/B Ratio	P/E Ratio	RoNW	Total Revenue (Cr)
Senores Pharmaceuticals Limited Current	4.46	55.05	23.6%	217
Ajanta Pharma Limited	9.55	40.3	23.2%	4,491
Alembic Pharmaceuticals Limited	4.20	32.3	13.3%	6,357
Caplin Point Laboratories Limited	7.24	37.3	24.2%	1,831
Gland Pharma Limited	3.31	42.0	9.26%	5,890
Strides Pharma Science Limited	2.84	32.4	4.48%	4,410

Offer for Sale

1
(a) Sell upto 21,00,000 equity shares (Rs 82.11/- Cr) of the selling shareholders of the company.

Fresh Issue

1
(a) Investment in one of the Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals ('Havix'), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility. ( Rs 107/- Cr )
2
(b) Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company. ( Rs 73.48/- Cr )
3
(c) Investment in the Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary ( Rs 20.22/- Cr )
4
(d) Funding the working capital requirements of the Company. ( Rs 43.26/- Cr )
5
(c) Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. ('SPI') and Ratnatris Pharmaceutical PrivateLimited ('Ratnatris') to fund their working capital requirements. ( Rs 59.48/- Cr )
6
(d) Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

✅ Check Your Mainboard IPO Allotment Result

Direct link to registrar — query by PAN / Application No. / DP Client ID.

Check Allotment →

⚠️

Disclaimer

No financial information whatsoever published herein, should be construed as an offer to buy or sell securities, or as information to make investment decisions, or as an official confirmation of any transaction. All matter published herein is purely for educational and informational purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor prior to making any actual investment decisions.

💬 Community Discussion

11 Comments

V
vish 27 Dec 2024, 17:27

hold
R
rakesh meena 27 Dec 2024, 05:33

after listening hold or sell plz suggest
R
Ravan 26 Dec 2024, 19:41

abhil coll me
A
akhil 26 Dec 2024, 13:43

63074
A
akhil 26 Dec 2024, 13:43

bharat call me please 70159
Y
YASH PAREKH 25 Dec 2024, 01:30

ipo main investment kar ne jesa hajn ?
B
Bharat 24 Dec 2024, 15:06

igi 530 aa gaya dekh lo sah
N
naman 24 Dec 2024, 12:10

gmp 50-60%
H
HEBBAL HANUMESH 23 Dec 2024, 14:47

Gmp?
M
Manish Dhokai 23 Dec 2024, 13:16

can anyone help??
M
Manish Dhokai 23 Dec 2024, 13:15

no information posted

Period	Total Income	Total Expenses	Profit After Tax (PAT)
Q1 FY25	183.35	153.95	23.94
FY24	217.34	192.40	32.71
FY23	39.02	26.58	8.43
FY22	14.63	13.49	0.99

Senores Pharmaceuticals Limited

Lot Size Calculator

Mainboard IPO Review

Mainboard IPO Timeline

IPO Subscription

Valuations (As on FY24)

Company Financials

Mainboard IPO At a Glance

Peers Comparison (As per FY26 / TTM)

About Company

Issue Objectives

Company Promoters

✅ Check Your Mainboard IPO Allotment Result

Disclaimer

💬 Community Discussion

✍️ Post a Comment